First Approvals Under EMA’s Adaptive Pathways May Be Just A Few Years Away
Executive Summary
The first marketing authorizations under the European Medicines Agency’s hotly debated adaptive pathways concept for getting drugs to patients faster could be granted in just a few years’ time.